Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function - PubMed (original) (raw)
. 1999 Jun 4;274(23):16228-34.
doi: 10.1074/jbc.274.23.16228.
Affiliations
- PMID: 10347178
- DOI: 10.1074/jbc.274.23.16228
Free article
Naturally occurring CCR5 extracellular and transmembrane domain variants affect HIV-1 Co-receptor and ligand binding function
O M Howard et al. J Biol Chem. 1999.
Free article
Abstract
Analysis of CCR5 variants in human immunodeficiency virus, type 1 (HIV-1), high risk cohorts led to the identification of multiple single amino acid substitutions in the amino-terminal third of the HIV-1 co-receptor CCR5 suggesting the possibility of protective and permissive genotypes; unfortunately, the low frequency of these mutations did not led to correlation with function. Therefore, we used analytical methods to assess the functional and structural significance of six of these variant receptors in vitro. These studies showed three categories of effects on CCR5 function. 1) Mutations in the first extracellular domain of CCR5 severely reduce specific ligand binding and chemokine-induced chemotaxis. 2) An extracellular domain variant, A29S, when co-expressed with CD4, supported HIV-1 infection whereas the others do not. 3) The transmembrane region variants of CCR5 support monotropic HIV-1 infection that is blocked by addition of some receptor agonists. Mutations in the first and second transmembrane domains increase RANTES (regulated on activation normal T-cell expressed) binding affinity but did not affect MIP1beta binding affinity presumably based on differences in ligand-receptor interaction sites. Furthermore, the CCR5 transmembrane mutants do not respond to RANTES with the classical bell-shaped chemotactic response curve, suggesting that they are resistant to RANTES-induced desensitization. These data demonstrate that single amino acid changes in the extracellular domains of CCR5 can have profound effects on both HIV-1 co-receptor and specific ligand-induced functions, whereas mutations in the transmembrane domain only affect the response to chemokine ligands.
Similar articles
- Variants of CCR5, which are permissive for HIV-1 infection, show distinct functional responses to CCL3, CCL4 and CCL5.
Dong HF, Wigmore K, Carrington MN, Dean M, Turpin JA, Howard OM. Dong HF, et al. Genes Immun. 2005 Oct;6(7):609-19. doi: 10.1038/sj.gene.6364247. Genes Immun. 2005. PMID: 16015368 Free PMC article. - The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.
Blanpain C, Doranz BJ, Bondue A, Govaerts C, De Leener A, Vassart G, Doms RW, Proudfoot A, Parmentier M. Blanpain C, et al. J Biol Chem. 2003 Feb 14;278(7):5179-87. doi: 10.1074/jbc.M205684200. Epub 2002 Dec 3. J Biol Chem. 2003. PMID: 12466283 - Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM, Wang ZX, Trent JO, Murray JL, Hu QX, DeLeeuw L, Moore PS, Chang Y, Peiper SC. Navenot JM, et al. J Mol Biol. 2001 Nov 9;313(5):1181-93. doi: 10.1006/jmbi.2001.5086. J Mol Biol. 2001. PMID: 11700073 - Role of C-C chemokine receptor type 5 in pathogenesis of malaria and its severe forms.
Ziliotto M, Ellwanger JH, Kulmann-Leal B, Pontillo A, Chies JAB. Ziliotto M, et al. Int J Immunogenet. 2024 Dec;51(6):369-379. doi: 10.1111/iji.12700. Epub 2024 Oct 25. Int J Immunogenet. 2024. PMID: 39449652 Review. - The Expanding Therapeutic Perspective of CCR5 Blockade.
Vangelista L, Vento S. Vangelista L, et al. Front Immunol. 2018 Jan 12;8:1981. doi: 10.3389/fimmu.2017.01981. eCollection 2017. Front Immunol. 2018. PMID: 29375583 Free PMC article. Review.
Cited by
- CCR5 promoter haplotypes differentially influence CCR5 expression on natural killer and T cell subsets in ethnically divergent HIV-1 uninfected South African populations.
Picton AC, Paximadis M, Tiemessen CT. Picton AC, et al. Immunogenetics. 2012 Nov;64(11):795-806. doi: 10.1007/s00251-012-0642-0. Epub 2012 Aug 15. Immunogenetics. 2012. PMID: 22893032 - Antiretrovirals to CCR5 CRISPR/Cas9 gene editing - A paradigm shift chasing an HIV cure.
Khan A, Paneerselvam N, Lawson BR. Khan A, et al. Clin Immunol. 2023 Oct;255:109741. doi: 10.1016/j.clim.2023.109741. Epub 2023 Aug 21. Clin Immunol. 2023. PMID: 37611838 Free PMC article. Review. - C-C chemokine receptor type five (CCR5): An emerging target for the control of HIV infection.
Barmania F, Pepper MS. Barmania F, et al. Appl Transl Genom. 2013 May 26;2:3-16. doi: 10.1016/j.atg.2013.05.004. eCollection 2013 Dec 1. Appl Transl Genom. 2013. PMID: 27942440 Free PMC article. Review. - Non-full-length Water-Soluble CXCR4QTY and CCR5QTY Chemokine Receptors: Implication for Overlooked Truncated but Functional Membrane Receptors.
Qing R, Tao F, Chatterjee P, Yang G, Han Q, Chung H, Ni J, Suter BP, Kubicek J, Maertens B, Schubert T, Blackburn C, Zhang S. Qing R, et al. iScience. 2020 Oct 28;23(12):101670. doi: 10.1016/j.isci.2020.101670. eCollection 2020 Dec 18. iScience. 2020. PMID: 33376963 Free PMC article. - African ancestry influences CCR5 -2459G>A genotype-associated virologic success of highly active antiretroviral therapy.
Cheruvu VK, Igo RP Jr, Jurevic RJ, Serre D, Zimmerman PA, Rodriguez B, Mehlotra RK. Cheruvu VK, et al. J Acquir Immune Defic Syndr. 2014 May 1;66(1):102-7. doi: 10.1097/QAI.0000000000000129. J Acquir Immune Defic Syndr. 2014. PMID: 24714069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials